Skip to main content
European Commission logo print header

SkinFactory 2.0: GMP-in-a-box

Project description

Promising 'skins' created from a patient's own skin cells are moving through clinical trials

The primary function of the skin is protection from mechanical impact, temperature changes, microorganisms, chemicals and radiation. Millions of people worldwide suffer from severe skin damage and removing that critical barrier exposes them to dangerous pathogens. Surgical interventions such as skin grafts are often painful and plagued by scarring. Further, multiple surgeries may be necessary to address the damage. SkinFactory 2.0 has developed the technology to produce novel, bioengineered skin grafts from a patient's own cells. The grafts are currently in phase II clinical trials in Europe. EU funding is supporting the application of cutting-edge 'Good Manufacturing Practices (GMP)-in-a-box' technology for en masse production of autologous cell therapies, overcoming current methods limited to small quantities under the strictest GMP guidelines.

Objective

CUTISS AG is a Swiss start-up company that develops customized human skin autografts (denovoSkin™) for the treatment of large skin defects like burns and malformations. DenovoSkin™ possesses the right features to minimize scarring after transplantation and is currently in clinical phase II in Europe. While manual production of denovoSkin™ is sufficient in the development phase and clinical trials, automation of the manufacturing process is essential to scale the technology for larger demand and internationalization, and to be competitive with current standard treatments. The proposed recruitment of an Innovation Associate will have significant impact on the development of an automated system for the manufacturing of denovoSkin™ (SkinFactory 2.0) enabling production lines at industrial scale and around the world. The grant will help to overcome the recruitment barriers of being a relatively unknown, small start-up enterprise that cannot compete with larger companies due to limited visibility, brand awareness, (perceived) career opportunities, salary and recruitment budget. The translation of the manual production process of denovoSkin™ to an GMP-in-a-box automation platform requires the employment of a multi-disciplinary researcher that understands both the cell biology and complex requirements of tissue engineering as well as the mechatronics and industrial design of automation. The envisaged Innovation Associate has to bring a multidisciplinary set of skills in to CUTISS and will have the opportunity to become an expert in the emerging field of bio-engineering. It is in the interest of the company to continue the employment after the initial year in order to develop the delivered prototype into an industrially producible end product. Successful market introduction of SkinFactory 2.0 will put CUTISS in the forefront of a new, emerging field of automated production of personalized, bio-engineered tissue, which is expected to change medicine radically.

Call for proposal

H2020-INNOSUP-2018-2020

See other projects for this call

Sub call

H2020-INNOSUP-2019-02

Coordinator

CUTISS AG
Net EU contribution
€ 183 125,00
Address
WEINBERGSTRASSE 35 WYSS TRANSLATIONAL CENTER ZURICH DENOVOS
8006 Zurich
Switzerland

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 183 125,00